DORZOLAMIDE-2%W/VDisorders of porphyrin and bilirubin metabolism
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Patients with porphyria should use topical sulfonamide therapy with caution because these medications can cause an acute attack. In patients with porphyria, the administration of oral sulfonamides is regarded as contraindicated.
How to manage the interaction:
Delzoc Eye Drops 5 ml should be used with caution in patients with porphyria as it may cause an acute attack.
DORZOLAMIDE-2%W/VObstructive and reflux uropathy
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Although Stevens-Johnson syndrome, toxic epidermal necrolysis, and other severe dermatologic reactions are uncommon in general, using sulfonamides is linked to significant increases in risk. As a result of sulfonamide hypersensitivity, hepatitis, pneumonitis, and interstitial nephritis have also been reported. Individuals with severe allergies, bronchial asthma, or AIDS should be treated with caution with topical sulfonamides due to the possibility of potentially serious hypersensitivity reactions in these individuals.
How to manage the interaction:
Delzoc Eye Drops 5 ml should be used with caution in patients with severe allergies, bronchial asthma or AIDS since these patients may be at increased risk for potentially severe hypersensitivity reactions. If you have severe headache, high fever, stomatitis (painful swelling and sores inside the mouth), rhinitis (stuffy nose), conjunctivitis (pink eye), urethritis (inflammation of the urethra), and balanitis (inflammation of the foreskin and head of the penis), contact your doctor immediately as these may be signs and symptoms of the Stevens-Johnson syndrome.
DORZOLAMIDE-2%W/VObstructive and reflux uropathy
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. In addition to methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anaemia, aplastic anaemia, purpura, coagulation problems, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia, the use of sulfonamides has also been linked to hematologic damage. Patients who already have blood dyscrasias or marrow suppression should use topical sulfonamide therapy with caution.
How to manage the interaction:
Delzoc Eye Drops 5 ml should be used with caution in patients with preexisting blood disorders or bone marrow suppression. Complete blood counts should be obtained regularly during prolonged therapy (more than 2 weeks). If you develop sore throat, fever, local infection, bleeding, pallor (pale skin), dizziness, or jaundice, contact your doctor immediately as these may be signs or symptoms of blood disease/disorder.
DORZOLAMIDE-2%W/VOther abnormal findings in urine
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Due to the sulfonamide and/or its N4-acetyl metabolite precipitating in the urinary tract, the usage of sulfonamides has been linked to crystalluria. There have been reports of renal toxicity, including hematuria, proteinuria, increased BUN and creatinine, uro- and nephrolithiasis, nephritis, toxic nephrosis, and more. During the use of sulfonamides, hydration and sufficient urine output (> 1.5 L/day) should be maintained. Patients who are dehydrated (for example, from severe vomiting or diarrhoea) may be more susceptible to developing crystalluria and lithiasis, hence it is important to encourage them to drink more liquids. Regular urinalysis and renal function testing should be carried out throughout extended therapy (> 2 weeks).
How to manage the interaction:
Delzoc Eye Drops 5 ml may be systemically absorbed when applied to the eye. Patients who are dehydrated are at increased risk for the development of crystalluria. Hence, hydration and adequate urinary output (greater than 1.5 L/day) should be maintained while using this medicine. Kidney function tests and urinalysis (urine test) should be performed regularly during prolonged therapy (more than 2 weeks).
DORZOLAMIDE-2%W/VOther diseases of liver
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Rarely have individuals using sulfonamides reported experiencing hepatotoxicity, including jaundice, diffuse hepatocellular necrosis, hypersensitivity hepatitis, and hepatic failure. Additionally, the liver only partially metabolises sulfonamides, which might build up in people with impaired liver function. Patients with liver illnesses should use topical sulfonamide therapy with caution.
How to manage the interaction:
Delzoc Eye Drops 5 ml should be used with caution in patients with liver disease.
DORZOLAMIDE-2%W/VOther disorders of kidney and ureter, not elsewhere classified
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Sulfonamides and their metabolites are filtered out by the kidney after absorption. Due to slower medication clearance, patients with renal impairment may be more susceptible to sulfonamide side effects. Sulfonamides can also result in toxic nephrosis, hematuria, proteinuria, increased BUN, and creatinine levels, in addition to renal damage related to crystalluria. During the use of sulfonamides, hydration and sufficient urine output (> 1.5 L/day) should be maintained. Regular urinalysis and renal function testing should be carried out throughout extended therapy (> 2 weeks). Some producers of topical sulfonamide medications advise against using them in patients with compromised renal function.
How to manage the interaction:
Delzoc Eye Drops 5 ml may be systemically absorbed when applied to the eye, and its metabolites are eliminated by the kidney. Hydration and adequate urinary output (greater than 1.5 L/day) should be maintained while using this medicine. Kidney function tests and urinalysis (urine test) should be performed regularly during prolonged therapy (more than 2 weeks).
DORZOLAMIDE-2%W/VObstructive and reflux uropathy
How does the disease interact with Delzoc Eye Drops 5 ml:
When sulfonamides are administered to the skin, eye, or mucosal membranes, they may be absorbed systemically. Sulfonamides are ingested, then eliminated and concentrated in the urine. Patients who have urinary blockage or retention should receive topical sulfonamide therapy carefully since excessive medication accumulation may occur.
How to manage the interaction:
Delzoc Eye Drops 5 ml may be systemically absorbed when applied to the eye and is excreted and concentrated in the urine. Hence, it should be used with caution in patients with urinary obstruction or retention since excessive drug accumulation may occur. Kidney function tests and urinalysis (urine test) should be performed regularly during prolonged therapy (more than 2 weeks).